Pharmaceutical Executive Europe - March 2007 - (Page 27)

Next Stop: Vienna Dr Christa Wirthumer-Hoche, co-chair of the 19th Annual DIA EuroMeeting, talks to Pharm Exec Europe about what this year’s event has in store. What new elements have you introduced into this year’s European meeting? Two special events will take place at this year’s EuroMeeting. The Japanese regulatory meeting will bring together representatives from the University of Tokyo and the Pharmaceuticals and Medical Devices Agency to discuss global drug development in Japan. Additionally, a special Austrian satellite meeting on 27 March will feature a discussion about the latest initiatives being undertaken by the Austrian Agency for Health and Food Safety. It will cover things like the future of the new Austrian Agency for Medicinal Products and Medical Devices; Austria as an attractive pharmaceutical research location; and the development and production of biopharmaceuticals in Vienna. To provide delegates with a uniquely Austrian cultural experience, the plenary session will include an Austrian String Concert followed by a special Viennese networking buffet reception. compounds and their regulation is constantly being challenged. We are hopeful, however, that by stimulating the research and development R&D of innovative medicines, we can improve R&D processes, design new paradigms and remove obstacles. To this end, the EuroMeeting will provide the latest information on important European initiatives, including paediatrics, advanced therapies, the technology platform, pharmacogenomics, pharmacovigilance, risk management planning and more. Furthermore, based on DIA’s strong relationship with the European Medicines Agency EMEA , this year’s meeting will include a session about the EMEA’s longterm strategy to improve the regulatory environment for medicinal products and stimulate R&D in the EU. Why was Vienna selected as this year’s location for the event? Austria is viewed by many as an important gateway to the region, and it represents a rich and mature pharmaceutical market. A member of the EU since 1995, the country is strategically placed among Berlin, Warsaw, Prague, Budapest, Belgrade, Milan, and Zurich — all are within 400 miles of Vienna. This location makes it ideal for companies wishing to reach a large number of European markets. 27 How is the event addressing the changing nature of drug development? In Europe, drug development is becoming more complex. Similarly, the development of pharmaceutical

Table of Contents for the Digital Edition of Pharmaceutical Executive Europe - March 2007

Linking People, Process and Technology
Building Alliances
Finding Success in Asia
Selecting South Africa
Advance from Europe
EDC: Are We Missing the Boat?
The Right Equipment
Next Stop: Vienna

Pharmaceutical Executive Europe - March 2007